These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

687 related items for PubMed ID: 28809995

  • 1. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
    Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, Goncalves J, Levi E, Callis Duffin K.
    J Drugs Dermatol; 2017 Aug 01; 16(8):801-808. PubMed ID: 28809995
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, Levi E, Duffin KC.
    J Drugs Dermatol; 2018 Feb 01; 17(2):221-228. PubMed ID: 29462231
    [Abstract] [Full Text] [Related]

  • 3. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J.
    J Eur Acad Dermatol Venereol; 2017 Mar 01; 31(3):507-517. PubMed ID: 27768242
    [Abstract] [Full Text] [Related]

  • 4. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O.
    J Dermatol; 2017 Aug 01; 44(8):873-884. PubMed ID: 28391657
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB.
    Br J Dermatol; 2015 Dec 01; 173(6):1387-99. PubMed ID: 26357944
    [Abstract] [Full Text] [Related]

  • 6. Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study.
    Strober B, Alikhan A, Lockshin B, Shi R, Cirulli J, Schafer P.
    J Dermatol Sci; 2019 Dec 01; 96(3):126-133. PubMed ID: 31787506
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P.
    J Eur Acad Dermatol Venereol; 2013 Mar 01; 27(3):e376-83. PubMed ID: 23030767
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V.
    J Eur Acad Dermatol Venereol; 2018 Mar 01; 32(3):397-402. PubMed ID: 29220542
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
    Van Voorhees AS, Stein Gold L, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M, Wang Y.
    J Am Acad Dermatol; 2020 Jul 01; 83(1):96-103. PubMed ID: 32032692
    [Abstract] [Full Text] [Related]

  • 10. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
    Bagel J, Samad AS, Stolshek BS, Aras GA, Chung JB, Kricorian G, Kircik LH.
    J Drugs Dermatol; 2018 Oct 01; 17(10):1078-1082. PubMed ID: 30365588
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
    Stein Gold L, Papp K, Pariser D, Green L, Bhatia N, Sofen H, Albrecht L, Gooderham M, Chen M, Paris M, Wang Y, Callis Duffin K.
    J Am Acad Dermatol; 2022 Jan 01; 86(1):77-85. PubMed ID: 34343599
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM.
    Lancet; 2012 Aug 25; 380(9843):738-46. PubMed ID: 22748702
    [Abstract] [Full Text] [Related]

  • 13. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
    Thaçi D, Kimball A, Foley P, Poulin Y, Levi E, Chen R, Feldman SR.
    J Eur Acad Dermatol Venereol; 2017 Mar 25; 31(3):498-506. PubMed ID: 27538241
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.
    Fiorillo L, Becker E, de Lucas R, Belloni-Fortina A, Armesto S, Elewski B, Maes P, Oberoi RK, Paris M, Zhang W, Zhang Z, Arkin L.
    J Am Acad Dermatol; 2024 Jun 25; 90(6):1232-1239. PubMed ID: 38266683
    [Abstract] [Full Text] [Related]

  • 15. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
    Armstrong A, Levi E.
    J Drugs Dermatol; 2017 Dec 01; 16(12):1240-1245. PubMed ID: 29240859
    [Abstract] [Full Text] [Related]

  • 16. Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy.
    Aljaser M, Amar L, Kircik LH.
    J Drugs Dermatol; 2019 Apr 01; 18(4):336-340. PubMed ID: 31012561
    [Abstract] [Full Text] [Related]

  • 17. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG.
    J Drugs Dermatol; 2013 Aug 01; 12(8):888-97. PubMed ID: 23986162
    [Abstract] [Full Text] [Related]

  • 18. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
    Bagel J, Nelson E, Keegan BR.
    J Drugs Dermatol; 2017 Oct 01; 16(10):957-962. PubMed ID: 29036248
    [Abstract] [Full Text] [Related]

  • 19. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D.
    J Eur Acad Dermatol Venereol; 2018 Jul 01; 32(7):1173-1179. PubMed ID: 29388335
    [Abstract] [Full Text] [Related]

  • 20. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, Sebastian M.
    J Am Acad Dermatol; 2016 Jul 01; 75(1):99-105. PubMed ID: 27021239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.